Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XPF-002 · 2 trials · 3 indications
Subjects recorded their pain scores 4 times each day (using an 11-point Likert numerical rating scale (NRS); 0-10, where 0 = no pain and 10 = worst pain imaginable). An average (mean) daily pain score was calculated. This measurement is the 'Change in mean daily pain score from baseline between the 3rd week of XPF-002 treatment and the 3rd week of placebo treatment for each subject'. Any missing mean daily pain scores were imputed using last observation carried forward (LOCF). The reduction in pain on each treatment compared to baseline is reported as a negative number. A larger negative number, indicates a greater reduction in pain. (A positive number would indicate pain was increased compared to baseline.)
Using diary cards, subjects recorded the use of all non-pharmacological cooling methods used to relieve their erythromelalgia (EM) pain each day during Treatment Period 2. A smaller average number of cooling uses each day in Treatment Period 2 indicates that subjects were in less pain/required less use of cooling to relieve their EM pain and vice versa.
| Arm | Type | Description |
|---|---|---|
| XPF-002 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| XPF-002 | DRUG | Twice daily application of XPF-002 ointment which contains 8% of the XPF-002 active ingredient |
| Placebo | DRUG | Twice daily application of Placebo ointment |
Inclusion Criteria: * Age 18 to 80 years (inclusive); * Males or females of non-childbearing potential (ie, 12 months or more of spontaneous amenorrhea, bilateral oophorectomy at least 6 months prior to randomization, hysterectomy with bilateral oophorectomy at least 6 months prior to randomization...
XPF-002 is an investigational small molecule being developed for pain conditions, specifically postherpetic neuralgia and primary erythromelalgia. It has been studied in clinical trials for these indications, though it remains in clinical development and is not approved.
XPF-002 is being developed by Xenon Pharmaceuticals Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol XENE. The company has conducted clinical trials evaluating the drug for pain-related conditions.
XPF-002 has completed Phase 2 clinical trials for postherpetic neuralgia and a Phase 1/2a exploratory study for primary erythromelalgia. It is an investigational drug still in clinical development and has not been approved by regulatory authorities.
XPF-002 has been studied in two completed trials: NCT01195636, a Phase 2 crossover study in 70 patients with postherpetic neuralgia, and NCT01486446, a Phase 2a exploratory study in 8 patients with primary or inherited erythromelalgia. Both trials were conducted in the United States.
No alternative names for XPF-002 have been disclosed. It is referred to solely by its development code XPF-002 in clinical trial records and by its developer, Xenon Pharmaceuticals.